Following the completion of the Human Genome Project in 2003, research in oncology has
progressively focused on the sequencing of cancer genomes, with the aim of better …

There are multiple applications of molecular tests in clinical oncology. Mutation analysis is
now routinely utilized for the diagnosis of hereditary cancer syndromes. Healthy carriers of …

PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO's
membership following publication or presentation of potentially practice-changing data from …

Background Patients with unfavourable subset cancer of unknown primary (CUP) have a
poor prognosis when treated with standard platinum-based chemotherapy. Whether first-line …

The benefit of molecularly-informed therapies in cancer of unknown primary (CUP) is
unclear. Here, we use comprehensive molecular characterization by whole genome/exome …

Identifying the primary site of metastatic cancer is critical to guiding the subsequent
treatment. Approximately 3–9% of metastatic patients are diagnosed with cancer of unknown …

Background Cancer of unknown primary (CUP), representing approximately 3-5% of all
malignancies, is defined as metastatic cancer where a primary site of origin cannot be found …

The finalization of the Human Genome Project in 2003 paved the way for a deeper
understanding of cancer, favouring a faster progression towards “personalized” medicine …

Importance Although profiling of gene expression and gene alterations by next-generation
sequencing (NGS) to predict the primary tumor site and guide molecularly targeted therapy …

Cancers of unknown primary (CUPs) are histologically confirmed, metastatic malignancies
with a primary tumor site that is unidentifiable on the basis of standard evaluation and …